Entering text into the input field will update the search result below

Provectus nabs fourth cancer combination therapy patent in U.S.

  • The USPTO has allowed Provectus' (OTC:PVCT) US patent application 15/804,357 for the combination of intratumoral PV-10 and systemic immunomodulatory therapy for the treatment of a range of solid tumor cancers.
  • This prospective new patent is the third continuation of USP 9,107,887, Provectus’ first and foundational cancer combination therapy patent granted by the USPTO in 2015.
  • It is also related to USP 9,808,524 and USP 9,839,688, which are also continuations and the Company’s second and third cancer combination therapy patents granted by the USPTO in 2017.
  • Pfizer is a co-assignee on all four awarded and allowed patents.

Recommended For You

About PVCT Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
PVCT--
Provectus Biopharmaceuticals, Inc.